These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 38250252)

  • 1. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations.
    Sackeyfio A; Lopes RD; Kovesdy CP; Cases A; Mallett SA; Ballew N; Keeley TJ; Garcia-Horton V; Ayyagari R; Camejo RR; Johansen KL; Sutton AJ; Dasgupta I
    Clin Kidney J; 2024 Jan; 17(1):sfad298. PubMed ID: 38250252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
    Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
    Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review.
    Damarlapally N; Thimmappa V; Irfan H; Sikandari M; Madhu K; Desai A; Pavani P; Zakir S; Gupta M; Khosa MM; Kotak S; Varrassi G; Khatri M; Kumar S
    Cureus; 2023 Oct; 15(10):e47430. PubMed ID: 38021836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Comparison between Vadadustat and Daprodustat Regarding Dose, Cost, and Safety of Treatment for Renal Anemia in Non-dialysis Patients with Chronic Kidney Diseases.
    Imai E; Imai A
    Intern Med; 2024 Jul; 63(13):1855-1861. PubMed ID: 37926547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis.
    Chen D; Niu Y; Liu F; Yang Y; Wang X; Li P; Chen X
    Front Pharmacol; 2023; 14():1163908. PubMed ID: 37292157
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
    Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
    Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials.
    Minutolo R; Liberti ME; Simeon V; Sasso FC; Borrelli S; De Nicola L; Garofalo C
    Clin Kidney J; 2024 Jan; 17(1):sfad143. PubMed ID: 38186871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H; Cheng Q; Wang J; Zhao X; Zhu S
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
    Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparison of four hypoxia-inducible factor prolyl hydroxylase inhibitors on drug potency and cost for treatment in patients with renal anemia.
    Imai E; Imai A
    Clin Exp Nephrol; 2024 Nov; 28(11):1090-1096. PubMed ID: 38767688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis.
    Ren S; Zhao Y; Wu J; Ren S; Feng Y
    Front Pharmacol; 2024; 15():1406588. PubMed ID: 39050745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease.
    Bartnicki P
    Biomedicines; 2024 Aug; 12(8):. PubMed ID: 39200348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease.
    Johnson HN; Prasad-Reddy L
    Ann Pharmacother; 2025 Jan; 59(1):71-80. PubMed ID: 38616529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases.
    Miao M; Wu M; Li Y; Zhang L; Jin Q; Fan J; Xu X; Gu R; Hao H; Zhang A; Jia Z
    Front Pharmacol; 2022; 13():837249. PubMed ID: 35281917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
    Doggrell SA
    Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
    Provenzano R; Szczech L; Leong R; Saikali KG; Zhong M; Lee TT; Little DJ; Houser MT; Frison L; Houghton J; Neff TB
    Clin J Am Soc Nephrol; 2021 Aug; 16(8):1190-1200. PubMed ID: 34362786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis.
    Zheng Q; Wang Y; Yang H; Sun L; Zhang P; Zhang X; Guo J; Liu YN; Liu WJ
    Am J Kidney Dis; 2023 Apr; 81(4):434-445.e1. PubMed ID: 36396085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
    Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
    N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
    Wish JB; Eckardt KU; Kovesdy CP; Fishbane S; Spinowitz BS; Berns JS
    Am J Kidney Dis; 2021 Nov; 78(5):709-718. PubMed ID: 34332007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Randomized Controlled Clinical Study to Investigate the Efficacy and Safety of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia Switched from Continuous Erythropoietin Receptor Activator Treatment.
    Sezai A; Abe M; Maruyama T; Taoka M; Sekino H; Tanaka M
    J Clin Med; 2024 May; 13(10):. PubMed ID: 38792306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.